ARTICLE | Deals
Janssen says half pipeline value will come from outside
What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities
June 29, 2023 1:29 PM UTC
In the last five years, Johnson & Johnson has spent nearly as much on deals as on internal R&D, with that balance carrying through to the value it’s derived from the assets, according to Janssen Global BD Head Nauman Shah, who says he aims to maintain that track record.
“We continue to see about half of our pipeline value coming from licensing agreements, partnerships and acquisitions,” Shah told BioCentury...